The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
Open accessAbstract
BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU) renal cell carcinoma (RCC) guideline panel has updated their evidence-based guidelines and recommendations for the management of RCC. Here we present a summary of the 2025 RCC guidelines updated with standardised methodology to provide reproducible evidence for the management of RCC. METHODS: For the 2025 update, a literature search was performed covering the period from May 1, 2023 to May 1, 2024 using the Medline, EMBASE, and Cochrane Libraries. The data search focused on meta-analyses, systematic reviews, randomised controlled trials (RCTs), and retrospective or controlled comparator-arm studies. Evidence was synthesised as outlined for all EAU guidelines. KEY FINDINGS AND LIMITATIONS: Clinical practise recommendations were updated in all chapters of the RCC guidelines on the basis of a structured literature search. The studies included were predominantly retrospective with matched or unmatched cohorts based on single- or multi-institutional data. Several prospective studies and RCTs provided data that resulted in recommendations based on higher levels of evidence. Specifically, updates include new recommendations on stereotactic body radiotherapy for localised RCC, adjuvant therapy, systemic therapy for clear-cell RCC in later lines, other subtypes, and a new chapter on hereditary RCC. CONCLUSIONS AND CLINICAL IMPLICATIONS: The 2025 RCC guidelines have been updated by a multidisciplinary panel of experts using methodological standards to provide a contemporary evidence base for the management of RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Ljungberg, B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.005 · Cited by 3,394
Self-citationMoch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.029 · Cited by 3,086
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060
Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.005 · Cited by 2,478
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Going from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Epidemiology of Renal Cell Carcinoma
Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J., Gore, J. L., Sun, M., Wood, C., & Russo, P. (2019) · European Urology · doi:10.1016/j.eururo.2018.08.036 · Cited by 1,618
Self-citationMotzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Research works printed but not linked: 55
- Mickisch, 2001, Guidelines on renal cell cancer, Eur Urol, 40, 252, 10.1159/000049783 · doi:10.1159/000049783
- Thorstenson, 2014, Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register, Scand J Urol, 48, 231, 10.3109/21681805.2013.864698 · doi:10.3109/21681805.2013.864698
- Alcala, 2022, The relationship between blood pressure and risk of renal cell carcinoma, Int J Epidemiol, 51, 1317
- Gansler, 2020, Prevalence of cigarette smoking among patients with different histologic types of kidney cancer, Cancer Epidemiol Biomarkers Prev, 29, 1406, 10.1158/1055-9965.EPI-20-0015 · doi:10.1158/1055-9965.epi-20-0015
- Sun, 2021, Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: results from Canadian Kidney Cancer information system, Can Urol Assoc J, 15, 132
- Sand, 2013, Incidentally detected renal cell carcinomas are highly associated with comorbidity and mortality unrelated to renal cell carcinoma, Scand J Urol, 47, 462, 10.3109/21681805.2013.777364 · doi:10.3109/21681805.2013.777364
- Voss, 2020, Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort, BJU Int, 125, 561, 10.1111/bju.15001 · doi:10.1111/bju.15001
- Leveridge, 2011, Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy, Eur Urol, 60, 578, 10.1016/j.eururo.2011.06.021 · doi:10.1016/j.eururo.2011.06.021
- Hora, 2023, European Association of Urology Guidelines Panel on Renal Cell Carcinoma update on the new World Health Organization classification of kidney tumours 2022: the urologist’s point of view, Eur Urol, 83, 97, 10.1016/j.eururo.2022.11.001 · doi:10.1016/j.eururo.2022.11.001
- Capitanio, 2023, A renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: proposal from the European Association of Urology guidelines panel, Eur Urol, 83, 3, 10.1016/j.eururo.2022.09.026 · doi:10.1016/j.eururo.2022.09.026
- Spaliviero, 2016, An arterial based complexity (ABC) scoring system to assess the morbidity profile of partial nephrectomy, Eur Urol, 69, 72, 10.1016/j.eururo.2015.08.008 · doi:10.1016/j.eururo.2015.08.008
- Hakky, 2014, Zonal NePhRO scoring system: a superior renal tumor complexity classification model, Clin Genitourin Cancer, 12, e13, 10.1016/j.clgc.2013.07.009 · doi:10.1016/j.clgc.2013.07.009
- Albiges, 2024, J Clin Oncol, 42, 4506, 10.1200/JCO.2024.42.16_suppl.4506 · doi:10.1200/jco.2024.42.16_suppl.4506
- Giles, 2022, Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: results from a global patient survey in 43 countries, Eur Urol Open Sci, 37, 3, 10.1016/j.euros.2021.12.003 · doi:10.1016/j.euros.2021.12.003
- Sprenkle, 2012, Comparison of open and minimally invasive partial nephrectomy for renal tumors 4–7 centimeters, Eur Urol, 61, 593, 10.1016/j.eururo.2011.11.040 · doi:10.1016/j.eururo.2011.11.040
- Badalato, 2012, Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach, BJU Int, 109, 1457, 10.1111/j.1464-410X.2011.10597.x · doi:10.1111/j.1464-410x.2011.10597.x
- Liu, 2021, A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma, Transl Androl Urol, 10, 1170, 10.21037/tau-20-1262 · doi:10.21037/tau-20-1262
- Porpiglia, 2021, Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (the RECORD 2 project), Surg Endosc, 35, 4295, 10.1007/s00464-020-07919-4 · doi:10.1007/s00464-020-07919-4
- Gill, 2007, Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors, J Urol, 178, 41, 10.1016/j.juro.2007.03.038 · doi:10.1016/j.juro.2007.03.038
- Peyronnet, 2016, Comparison of 1800 robotic and open partial nephrectomies for renal tumors, Ann Surg Oncol, 23, 4277, 10.1245/s10434-016-5411-0 · doi:10.1245/s10434-016-5411-0
- Kowalewski, 2024, Randomized controlled feasibility trial of robot-assisted versus conventional open partial nephrectomy: the ROBOCOP II study, Eur Urol Oncol, 7, 91, 10.1016/j.euo.2023.05.011 · doi:10.1016/j.euo.2023.05.011
- Cignoli, 2023, Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time, BJU Int, 132, 283, 10.1111/bju.16009 · doi:10.1111/bju.16009
- Sharma, 2023, Off-clamp versus on-clamp robot-assisted partial nephrectomy: a propensity-matched analysis, Eur Urol Oncol, 6, 525, 10.1016/j.euo.2023.04.005 · doi:10.1016/j.euo.2023.04.005
- Wood, 2018, Local tumor bed recurrence following partial nephrectomy in patients with small renal masses, J Urol, 199, 393, 10.1016/j.juro.2017.09.072 · doi:10.1016/j.juro.2017.09.072
- Bensalah, 2010, Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery, Eur Urol, 57, 466, 10.1016/j.eururo.2009.03.048 · doi:10.1016/j.eururo.2009.03.048
- Kim, 2016, Treatment of patients with positive margins after partial nephrectomy, J Urol, 196, 301, 10.1016/j.juro.2016.05.078 · doi:10.1016/j.juro.2016.05.078
- Antic, 2015, Partial nephrectomy for renal tumors: lack of correlation between margin status and local recurrence, Am J Clin Pathol, 143, 645, 10.1309/AJCP7LKLZ8JSJQRG · doi:10.1309/ajcp7lklz8jsjqrg
- Bekema, 2013, Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma, Eur Urol, 64, 799, 10.1016/j.eururo.2013.04.033 · doi:10.1016/j.eururo.2013.04.033
- Capitanio, 2011, Lymph node dissection in renal cell carcinoma, Eur Urol, 60, 1212, 10.1016/j.eururo.2011.09.003 · doi:10.1016/j.eururo.2011.09.003
- Gershman, 2018, Radical nephrectomy with or without lymph node dissection for high risk nonmetastatic renal cell carcinoma: a multi-institutional analysis, J Urol, 199, 1143, 10.1016/j.juro.2017.11.114 · doi:10.1016/j.juro.2017.11.114
- Tsui, 2000, Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria, J Urol, 163, 1090, 10.1016/S0022-5347(05)67699-9 · doi:10.1016/s0022-5347(05)67699-9
- Gershman, 2017, Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection, Eur Urol, 72, 300, 10.1016/j.eururo.2016.12.027 · doi:10.1016/j.eururo.2016.12.027
- Lardas, 2016, Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus, Eur Urol, 70, 265, 10.1016/j.eururo.2015.11.034 · doi:10.1016/j.eururo.2015.11.034
- Kirkali, 2007, A critical analysis of surgery for kidney cancer with vena cava invasion, Eur Urol, 52, 658, 10.1016/j.eururo.2007.05.009 · doi:10.1016/j.eururo.2007.05.009
- May, 2009, Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma, Br J Radiol, 82, 724, 10.1259/bjr/17514226 · doi:10.1259/bjr/17514226
- Neves, 2024, Nephron sparing treatment (NEST) for small renal masses: a feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy, Eur Urol, 85, 333, 10.1016/j.eururo.2023.07.012 · doi:10.1016/j.eururo.2023.07.012
- Prins, 2017, Renal cell carcinoma: alternative nephron-sparing treatment options for small renal masses, a systematic review, J Endourol, 31, 963, 10.1089/end.2017.0382 · doi:10.1089/end.2017.0382
- Widdershoven, 2021, Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up, Abdom Radiol, 46, 373, 10.1007/s00261-020-02613-4 · doi:10.1007/s00261-020-02613-4
- Correa, 2019, The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis, Eur Urol Focus, 5, 958, 10.1016/j.euf.2019.06.002 · doi:10.1016/j.euf.2019.06.002
- Ali, 2022, The role of stereotactic ablative body radiotherapy in renal cell carcinoma, Eur Urol, 82, 613, 10.1016/j.eururo.2022.06.017 · doi:10.1016/j.eururo.2022.06.017
- Tabbara, 2023, Current approaches in surgical and immunotherapy-based management of renal cell carcinoma with tumor thrombus, Biomedicines., 11, 204, 10.3390/biomedicines11010204 · doi:10.3390/biomedicines11010204
- Bex, 2022, Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx), J Clin Oncol, 40, 289, 10.1200/JCO.2022.40.6_suppl.289 · doi:10.1200/jco.2022.40.6_suppl.289
- Bedke J, Ghanem YA, Albiges L, et al. Updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.01.014. · doi:10.1016/j.eururo.2025.01.014
- Bex, 2018, Updated European Association of Urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma, Eur Urol, 74, 805, 10.1016/j.eururo.2018.08.008 · doi:10.1016/j.eururo.2018.08.008
- Appleman, 2019, Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer research group (E2810), J Clin Oncol, 37, 4502, 10.1200/JCO.2019.37.15_suppl.4502 · doi:10.1200/jco.2019.37.15_suppl.4502
- Albiges, 2025, Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): final results of COSMIC-313, J Clin Oncol, 44, 438, 10.1200/JCO.2025.43.5_suppl.438 · doi:10.1200/jco.2025.43.5_suppl.438
- Tannir, 2024, Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial, J Clin Oncol, 42, 363, 10.1200/JCO.2024.42.4_suppl.363 · doi:10.1200/jco.2024.42.4_suppl.363
- Beckermann, 2024, Long-term survival in patients with relapsed/refractory advanced renal cell carcinoma treated with tivozanib: analysis of the phase III TIVO-3 trial, Oncologist, 29, 254, 10.1093/oncolo/oyad348 · doi:10.1093/oncolo/oyad348
- Ornstein, 2018, Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1/PD-L1 inhibitors, J Clin Oncol, 36, 4517, 10.1200/JCO.2018.36.15_suppl.4517 · doi:10.1200/jco.2018.36.15_suppl.4517
- Lee, 2023, First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: results of the phase 2 KEYNOTE-B61 study, J Clin Oncol, 41, 4518, 10.1200/JCO.2023.41.16_suppl.4518 · doi:10.1200/jco.2023.41.16_suppl.4518
- Lee, 2023, Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: updated results from a phase 2 trial, J Clin Oncol, 41, 4537, 10.1200/JCO.2023.41.16_suppl.4537 · doi:10.1200/jco.2023.41.16_suppl.4537
- Bergmann, 2024, LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: results of the SUNNIFORECAST trial, Ann Oncol, 35, S1263, 10.1016/j.annonc.2024.08.2318 · doi:10.1016/j.annonc.2024.08.2318
- Przybycin, 2013, Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens, Adv Anatom Pathol, 20, 245, 10.1097/PAP.0b013e318299b7c6 · doi:10.1097/pap.0b013e318299b7c6
- Dabestani, 2019, Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scand, J Urol, 53, 14
- Capitanio, 2020, Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer, Eur Urol Oncol, 3, 209, 10.1016/j.euo.2019.02.006 · doi:10.1016/j.euo.2019.02.006
Cited by
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04266-7
Metadata
- Authors
- Bex, A., Ghanem, Y. A., Albiges, L., Bonn, S., Campi, R., Capitanio, U., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., Lund, L., Marconi, L., Palumbo, C., Pignot, G., Powles, T., Schouten, N., Tran, M., Volpe, A., & Bedke, J.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2025-06
- Volume
- 87
- Issue
- 6
- Pages
- 683-696
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W4408674287
- Cited by
- 345
- References
- 77
- FWCI
- 206.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. https://app.cochat.ai/papers/10.1016/j.eururo.2025.02.020
- The paper
- Bex, A., Ghanem, Y. A., Albiges, L., Bonn, S., Campi, R., Capitanio, U., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., Lund, L., Marconi, L., Palumbo, C., Pignot, G., Powles, T., Schouten, N., Tran, M., Volpe, A., & Bedke, J. (2025). European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. European Urology. https://doi.org/10.1016/j.eururo.2025.02.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.